Form 4: 4D Molecular Therapeutics Chief Legal Officer Scott Bizily Reports Stock Transactions
SEC Form 4 Filing
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.
Summary
- On May 16, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, executed transactions involving the company's common stock.
- Bizily exercised stock options to acquire 500 shares at $6.49 and 1,250 shares at $8.04.
- He then sold 1,283 shares at a weighted average price of $25.342 and 467 shares at a weighted average price of $25.7543.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on October 10, 2023.
- Following these transactions, Bizily directly owns 1,737 shares of common stock and holds options to purchase 51,629 additional shares.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the trading activities of company executives.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| October 10, 2023 | Date the Reporting Person adopted the 10b5-1 trading plan |
| June 16, 2022 | Vesting Commencement Date for 500 shares at $6.49 |
| September 1, 2022 | Vesting Commencement Date for 1,250 shares at $8.04 |
| May 16, 2024 | Date of stock option exercise and stock sale transactions |
| June 17, 2032 | Expiration date for stock options to buy 500 shares at $6.49 |
| August 31, 2032 | Expiration date for stock options to buy 1,250 shares at $8.04 |
| May 20, 2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.